(Reuters) - Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor ...

Estimated to save individual Accredo patients around $4,000 per year Biosimilar price will be more than 80% lower than Stelara list price Accredo patients benefit from the specialty pharmacy's best-in ...

There might just be a silver lining for Johnson & Johnson in the FDA's recent approval of Amgen’s Stelara biosimilar. That’s because the coming entry of a cheaper copycat presents J&J with an ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations with ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...

WASHINGTON — Ninety-eight days may end up costing Johnson & Johnson. When Medicare this week announced the first 10 medicines that will be included in its brand-new drug price negotiation program, a J ...